FDA approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with type 1 plasminogen deficiency, also referred to as hypoplasminogenemia.
Read more: FDA Approves First Treatment for Patients with Plasminogen Deficiency, a Rare Genetic Disorder